News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
